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Disparate Antiviral Responses in 
Molluscum contagiosum Virus–
Induced Skin Lesions
Melissa Swiecki1 and Marco Colonna1
Molluscum contagiosum virus (McV) is a poxvirus that causes tumor-like skin 
lesions. New evidence indicates that plasmacytoid dendritic cells, type I inter-
feron production, and interferon-induced dendritic cells have prominent roles 
in anti-McV responses, and these features characterize the inflammatory 
response in lesions that will likely undergo spontaneous regression.
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mcV infection
Skin is a barrier that protects against 
physical and chemical insults as well 
as pathogen invasion. It is composed of 
outer and inner layers (epidermis and 
dermis) that are occupied and surveyed 
by cells of the immune system. In the 
steady state, macrophages, mast cells, 
Langerhans cells, dermal dendritic cells 
(DCs), and γδ T cells (in mice) consti-
tute the majority of immune cells in the 
skin. However, after injury or infection, 
monocytes, plasmacytoid dendritic 
cells (pDCs), αβ T cells, and B cells are 
recruited to play roles in innate and 
adaptive responses (Nestle et al., 2009). 
MCV is a DNA poxvirus that causes 
benign tumor-like cutaneous lesions. 
In healthy individuals, these lesions are 
often spontaneously cleared, but little 
is known about the cellular events that 
lead to disease resolution. In this issue, 
Vermi and colleagues (2011) describe 
two types of skin lesions in patients 
infected with MCV and identify a novel 
population of DCs, IFN-DCs, that infil-
trate MCV lesions destined to undergo 
spontaneous regression.
noninflamed versus inflammatory  
mcV-induced skin lesions
After careful histological examination 
of biopsies, Vermi et al. were able 
to divide MCV-induced skin lesions 
into two groups: noninflamed (NI-
MC) and inflamed (I-MC) (Figure 1). 
NI-MCs were sparsely populated with 
CD45+ leukocytes, which included 
CD163+ macrophages and CD11c+ 
DCs. By contrast, I-MCs were heav-
ily infiltrated by CD45+ cells such as 
CD163+ macrophages, CD20+ B cells, 
perforin+CD56+ natural killer cells, and 
both CD8+ and CD4+ T-cell populations. 
As with many other viral infections, 
clearance of poxviruses relies on vigor-
ous CD8+ T-cell responses (Stanford and 
McFadden, 2005). Indeed, it was found 
that CD8+ T cells in I-MCs displayed a 
cytotoxic phenotype and expressed 
the activation marker CD30. Antiviral 
CD8+ T-cell responses to poxviruses are 
dependent on Th1 cytokines (Stanford 
and McFadden, 2005). Phenotypic 
analysis of infiltrating CD4+ T cells 
revealed nuclear expression of T-bet, a 
transcription factor that directs Th1 lin-
eage commitment (Szabo et al., 2000).
The robust infiltrate of effector 
cells in I-MCs is strong evidence of an 
ongoing, productive antiviral immune 
response. But how is this response initi-
ated in some MCV-induced skin lesions 
but not in others? Another prominent 
feature of I-MCs but not NI-MCs is the 
presence of pDCs (Figure 1). pDCs were 
identified in skin lesions as positive 
for CD123 (IL-3R), CD303 (BDCA-2), 
TCL1, CD2AP, and BCL11A. pDCs are 
a unique population of bone marrow–
derived leukocytes that secrete type I 
interferons (IFN-I), inducing an antiviral 
state. pDCs also produce IL-12, IL-6, 
and chemokines that contribute to Th1 
polarization of CD4+ T cells, differen-
tiation of B cells into immunoglobulin-
secreting plasma cells, and recruitment 
of T cells, respectively (Gilliet et al., 
2008). pDCs express major histocom-
patibility complex and costimulatory 
molecules and therefore may partici-
pate directly in antigen presentation 
and cross-priming (Villadangos and 
Young, 2008). Thus, the localization of 
pDCs in I-MCs suggests that they have 
a prominent and beneficial role during 
MCV infection. But what are the factors 
that drive the recruitment of pDCs into 
I-MCs, and how do they modulate anti-
MCV responses?
pDc accumulation and IFn-I production
Under homeostatic conditions, pDCs 
circulate in the blood and reside in the 
spleen, liver, thymus, bone marrow, 
and lymph nodes. pDCs are normally 
absent from healthy skin; however, in 
pathological circumstances such as 
injury, viral infections, or inflammatory 
disorders they can accumulate there. 
The trafficking of pDCs to the skin is 
not well understood but could be medi-
ated by chemoattractants produced by 
resident skin cells in perturbed areas 
(Sozzani et al., 2010). Prochemerin is 
an inactive precursor protein released 
constitutively by dermal endothelial 
cells, fibroblasts, and keratinocytes. 
After tissue injury, serine proteases are 
released and then cleave prochemerin 
into its active form, chemerin. pDCs 
are able to migrate in response to 
chemerin because they express the G 
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protein–coupled receptor ChemR23. 
Although Vermi and colleagues (2011) 
do not address the mechanisms under-
lying pDC migration into I-MCs, they 
and others have demonstrated previ-
ously that chemerin does facilitate pDC 
migration into lymphoid tissues and 
inflamed skin (Sozzani et al., 2010). 
Thus, chemerin is an attractive candi-
date for driving pDCs into I-MCs.
So why are pDCs recruited only to 
some MCV-induced lesions? Patients 
and dermatologists have reported that 
manipulation of MCV-induced skin 
lesions results in the extrusion of mollus-
cum bodies into the dermis where they 
can contact immune cells, often leading 
to perilesional erythema followed by 
regression. Perhaps aggravation of some 
lesions but not others induces proteolytic 
cleavage of prochemerin into chemerin, 
resulting in trafficking and accumula-
tion of pDCs. CXCR3 ligands might 
also be important in recruiting pDCs to 
MCV-induced lesions. Gene expression 
in MCV-induced skin lesions indicated 
strong upregulation of CXCL10 in I-MCs 
compared with NI-MCs. Previously it 
was reported that pDCs accumulat-
ing in skin lesions caused by Varicella 
zoster virus expressed CXCR3 (Gerlini 
et al., 2006). Additional factors that 
could attract pDCs to damaged skin are 
adenosine, F2L, C3a, and C5a (Sozzani 
et al., 2010).
I-MCs containing pDCs displayed 
upregulation of IFN-inducible pro-
teins such as MxA and phosphoryla-
tion of STAT1, which modulates the 
transcription of IFN-stimulated genes. 
These data suggest that pDCs recruited 
to I-MCs secrete IFN-I. IFN-I not only 
confers resistance to viral infections but 
also promotes natural killer cell, DC, 
T-cell, and B-cell function (Gilliet et al., 
2008). What remains open for debate is 
how IFN-I is induced by pDCs in I-MCs. 
pDCs sense viruses and modified self-
nucleic acids through two endosomal 
sensors: Toll-like receptors (TLR) 7 and 
9 (Gilliet et al., 2008). Upon engage-
ment with nucleic acid ligands, TLR7/9 
signal through the MyD88–IRF7 
pathway, leading to transcriptional acti-
vation of IFN-I genes. One possibility is 
that pDCs sense MCV directly through 
TLR9, leading to the production of 
IFN-I. Alternatively, pDCs may be 
stimulated by direct cell-to-cell contact 
with MCV-infected cells, as is the case 
for hepatitis C virus (Takahashi et al., 
2010). Another possibility is that pDCs 
in I-MCs secrete IFN-I in response to 
self-DNA or self-RNA modified by the 
cathelicidin LL-37. It has been reported 
that in psoriasis, damaged keratinocytes 
release LL-37, which converts self-
nucleic acids into potent stimulators of 
pDCs (Gilliet et al., 2008).
consequences of IFn-I production: 
IFn-Dcs
Another key observation of Vermi and 
colleagues (2011) is the identification 
of a novel DC subset in I-MCs. This DC 
population, CD123+CD11c+, was not 
found in NI-MCs. Phenotypic analy-
ses revealed that most of these cells 
were positive for the markers CD14, 
CD16, CD40, and HLA-DR and that 
they expressed MxA and phospho-
rylated STAT1, reflecting their expo-
sure to IFN-I. A proportion of this 
subset also expressed CD83, CCR7, 
and CD208/DC-LAMP. Vermi et al. 
(2011) called these DCs “IFN-DCs” 
because they resembled IFN-DCs 
obtained in vitro after exposing mono-
cytes to GM-CSF and IFN-I (Santini et 
al., 2000). To corrob orate further that 
CD123+CD11c+ cells were the in vivo 
equivalent of in vitro–derived IFN-DCs, 
the investigators evaluated granzyme 
B and TNF-related apoptosis-inducing 
ligand (TRAIL) expression. Indeed, 
CD123+CD11c+ cells expressed both 
molecules and were localized to areas 
containing apoptotic keratinocytes.
What is the function of IFN-DCs 
in the MCV-induced skin lesions? 
Interestingly, cell death was only 
observed in I-MCs but not in NI-MCs, 
as determined by antiactive caspase 3 
staining. Therefore, IFN-DCs could be 
engaging in granzyme B- and TRAIL-
dependent responses. They could also 
be producing IFN-I and participat-
ing in the uptake and processing of 
viral antigens. I-MCs displayed greater 
expression of major histocompatibility 
complex molecules, TAP1, TAP2, and 
nuclear translocation of NF-κB.
Figure 1. roles of pDcs and IFn-Dcs in effective anti-mcV responses. Noninflamed MCV-induced 
skin lesions (NI-MCs) are sparsely populated with macrophages and dendritic cells. In inflamed 
MCV-induced skin lesions (I-MCs), (1) pDCs are recruited in a chemerin-dependent manner. (2) 
pDCs are activated through Toll-like receptor–7/9 in I-MCs by MCV directly, through contact with 
MCV-infected keratinocytes, or by self-nucleic acids modified by LL-37. (3) Activated pDCs produce 
IFN-I and other cytokines/chemokines such as IL-6, IL-12, CCL3, and CCL4. (4) IFN-I induces the 
differentiation of monocytes into IFN-DCs, which can secrete IFN-I, kill virus-infected cells via 
granzyme B (GrB) and/or TNF-related apoptosis-inducing ligand (TRAIL), and present viral antigens 
to T cells. CTL, cytotoxic T lymphocyte; DC, dendritic cell; IFN-DC, IFN-induced dendritic cell; 
MCV, Molluscum contagiosum virus; MO, monocyte; NK, natural killer cell; Mφ, macrophage;  
pDC, plasmacytoid dendritic cell.
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Infection versus autoimmunity
In viral infections and in skin cancer, 
creating an inflammatory environment 
appears to be a critical step in the elimi-
nation of virally infected cells and tumor 
cells. Imiquimod is a topical TLR7/8 ago-
nist that is used in a cream form to treat 
skin lesions caused by human papilloma 
virus and MCV and certain skin cancers. 
The mechanisms of imiquimod-induced 
regression of skin lesions are not com-
pletely understood; however, hallmarks 
of treatment include pDC accumulation 
and IFN-I production (Stary et al., 2007). 
Accumulation and activation of pDCs in 
skin lesions is not always ideal, however. 
In chronic inflammatory/autoimmune 
diseases such as psoriasis, systemic 
lupus erythematosus, and lichen planus, 
pDC infiltration and activation results 
in excessive DC maturation and auto-
reactive B- and T-cell activation (Conrad 
et al., 2009). It will be worth investi-
gating whether the IFN-DCs described 
by Vermi et al. (2011) are also found 
in skin lesions of psor iasis, systemic 
lupus erythe ma tosus, or lichen planus 
and whether they contribute to disease 
pathogenesis. Understanding the chain 
of events that occur in the skin during 
viral infection, cancer and chronic 
inflammatory disorders may open new 
avenues of therapeutic intervention.
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consequences of Psychological 
Distress in Adolescents with Acne
Laurent Misery1,2
Acne may cause psychological distress that is associated with many psychiatric dis-
orders. In this issue, Halvorsen et al. report suicidal ideation, mental health prob-
lems, and affective isolation to be relatively frequent in adolescents with acne. This 
report suggests that adverse events that have been attributed to therapies for acne, 
including suicidal ideation and depression, may reflect the burden of substantial 
acne rather than the effect of medications.
Journal of Investigative Dermatology (2011) 131, 290–292. doi:10.1038/jid.2010.375
Psychological distress
Adolescence is known to be a period 
especially associated with psychological 
distress. Adolescents are psychologically 
vulnerable, and they tend to be 
sensitive to modifications in their 
bodies and appearance. Studies have 
revealed the burden of acne to dimin-
ish adolescents’ quality of life and to 
impact their global self-esteem (Dreno, 
2006; Fried and Wechsler, 2006). Girls 
and boys with acne have lower self-
attitude, more feelings of uselessness, 
fewer feelings of pride, lower self-
worth, and lower body satisfaction 
than those without acne. In a regres-
sion model for body mass index and 
depressive symptoms, acne explains 
significantly lower self-attitude (for 
boys) and poor self-worth (for girls) 
(Dalgard et al., 2008).
Psychiatric consequences
Acne-related psychological suffering 
could be consequently linked to the 
occurrence of psychiatric disorders such 
as anxiety, depression, and suicidal ide-
ation. Many studies have shown these 
disorders to be present in patients with 
acne, but the impact of these studies 
was often diminished by small sample 
size and absent or doubtful controls 
(Niemeier et al., 2006; Tan, 2004). A 
few large studies have demonstrated 
depressive symptoms to be present in 
patients with acne (Purvis et al., 2006). 
However, a population-based study 
comparing the frequency of suicide and 
suicidal ideation in teenagers, with and 
without acne, has been lacking. Such a 
study could influence our understand-
ing of the role of isotretinoin, an acne 
therapy, in suicides.
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